RU2674036C2 - Индукция иммунологической толерантности, используя метотрексат - Google Patents
Индукция иммунологической толерантности, используя метотрексат Download PDFInfo
- Publication number
- RU2674036C2 RU2674036C2 RU2013155618A RU2013155618A RU2674036C2 RU 2674036 C2 RU2674036 C2 RU 2674036C2 RU 2013155618 A RU2013155618 A RU 2013155618A RU 2013155618 A RU2013155618 A RU 2013155618A RU 2674036 C2 RU2674036 C2 RU 2674036C2
- Authority
- RU
- Russia
- Prior art keywords
- methotrexate
- cells
- matg
- treatment
- alemtuzumab
- Prior art date
Links
- 229960000485 methotrexate Drugs 0.000 title claims abstract description 527
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims abstract description 526
- 230000006698 induction Effects 0.000 title claims description 12
- 230000006058 immune tolerance Effects 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 232
- 229960000548 alemtuzumab Drugs 0.000 claims abstract description 188
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims abstract description 174
- 102000045921 human GAA Human genes 0.000 claims abstract description 174
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 67
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 60
- 230000001965 increasing effect Effects 0.000 claims abstract description 51
- 230000004044 response Effects 0.000 claims abstract description 36
- 230000005875 antibody response Effects 0.000 claims abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 251
- 230000001900 immune effect Effects 0.000 claims description 82
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 57
- 238000002054 transplantation Methods 0.000 claims description 31
- 230000015572 biosynthetic process Effects 0.000 claims description 28
- 230000005784 autoimmunity Effects 0.000 claims description 25
- 210000003289 regulatory T cell Anatomy 0.000 claims description 24
- 210000001519 tissue Anatomy 0.000 claims description 24
- 201000006417 multiple sclerosis Diseases 0.000 claims description 23
- 210000002707 regulatory b cell Anatomy 0.000 claims description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 20
- 210000004698 lymphocyte Anatomy 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 102000034238 globular proteins Human genes 0.000 claims description 8
- 108091005896 globular proteins Proteins 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 7
- 230000005867 T cell response Effects 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 5
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 4
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 210000005084 renal tissue Anatomy 0.000 claims description 2
- 230000003313 weakening effect Effects 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 69
- 239000003814 drug Substances 0.000 abstract description 51
- 229940107955 thymoglobulin Drugs 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 18
- 241001529936 Murinae Species 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 144
- 241001465754 Metazoa Species 0.000 description 113
- 210000004027 cell Anatomy 0.000 description 113
- 108090000174 Interleukin-10 Proteins 0.000 description 63
- 102000003814 Interleukin-10 Human genes 0.000 description 60
- 229940103023 myozyme Drugs 0.000 description 57
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 55
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 55
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 54
- 230000004069 differentiation Effects 0.000 description 52
- 210000000952 spleen Anatomy 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 41
- 229940124597 therapeutic agent Drugs 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 238000005755 formation reaction Methods 0.000 description 27
- 230000003325 follicular Effects 0.000 description 25
- 238000002560 therapeutic procedure Methods 0.000 description 24
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 230000001404 mediated effect Effects 0.000 description 22
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 21
- 102000043738 human CD52 Human genes 0.000 description 21
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 20
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 230000007423 decrease Effects 0.000 description 20
- 210000002216 heart Anatomy 0.000 description 20
- 230000028993 immune response Effects 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 238000000684 flow cytometry Methods 0.000 description 18
- 208000023275 Autoimmune disease Diseases 0.000 description 17
- 230000003442 weekly effect Effects 0.000 description 16
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 14
- 230000003285 pharmacodynamic effect Effects 0.000 description 14
- 210000001165 lymph node Anatomy 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 238000011830 transgenic mouse model Methods 0.000 description 12
- 241000699660 Mus musculus Species 0.000 description 11
- 230000000735 allogeneic effect Effects 0.000 description 11
- 230000028996 humoral immune response Effects 0.000 description 11
- 230000007170 pathology Effects 0.000 description 11
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 10
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 10
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229960004641 rituximab Drugs 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 9
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000007928 intraperitoneal injection Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000009163 protein therapy Methods 0.000 description 9
- 206010052779 Transplant rejections Diseases 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 230000008105 immune reaction Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000016679 alpha-Glucosidases Human genes 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002641 enzyme replacement therapy Methods 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 210000003826 marginal zone b cell Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000001685 thyroid gland Anatomy 0.000 description 6
- 102100032912 CD44 antigen Human genes 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 102100025877 Complement component C1q receptor Human genes 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
- 101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 description 5
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 5
- 102100033467 L-selectin Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000219061 Rheum Species 0.000 description 5
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000011284 combination treatment Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000779 depleting effect Effects 0.000 description 5
- 230000007365 immunoregulation Effects 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 229960000598 infliximab Drugs 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000036647 reaction Effects 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100032768 Complement receptor type 2 Human genes 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 206010025327 Lymphopenia Diseases 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- 102000003911 Thyrotropin Receptors Human genes 0.000 description 4
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000011316 allogeneic transplantation Methods 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 244000144993 groups of animals Species 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 231100001023 lymphopenia Toxicity 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 4
- 210000001631 vena cava inferior Anatomy 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102000013135 CD52 Antigen Human genes 0.000 description 3
- 108010065524 CD52 Antigen Proteins 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000031220 Hemophilia Diseases 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 108010036012 Iodide peroxidase Proteins 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 101150057615 Syn gene Proteins 0.000 description 3
- 102000014267 Thyroid peroxidases Human genes 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 230000001494 anti-thymocyte effect Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 230000036732 histological change Effects 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 229960005027 natalizumab Drugs 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- -1 phosphatidylinositol lipid Chemical class 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 206010040400 serum sickness Diseases 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000024664 tolerance induction Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 102100039564 Leukosialin Human genes 0.000 description 2
- 241000551546 Minerva Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 201000001322 T cell deficiency Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003460 anti-nuclear Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000004052 folic acid antagonist Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002820 Antisocial behaviour Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102100027991 Beta/gamma crystallin domain-containing protein 1 Human genes 0.000 description 1
- 101710154744 Beta/gamma crystallin domain-containing protein 1 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100369802 Caenorhabditis elegans tim-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 241001133757 Carpentaria Species 0.000 description 1
- 102100034755 Centrosomal protein of 85 kDa Human genes 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 1
- 101000859450 Homo sapiens Beta/gamma crystallin domain-containing protein 2 Proteins 0.000 description 1
- 101100383049 Homo sapiens CD52 gene Proteins 0.000 description 1
- 101000945822 Homo sapiens Centrosomal protein of 85 kDa Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 101150085950 IL10 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 238000011794 NU/NU nude mouse Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 101150111548 SH3BGRL3 gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 108010056760 agalsidase beta Proteins 0.000 description 1
- 229940022705 aldurazyme Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002691 anti-thymic effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229940022836 benlysta Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940049197 cerezyme Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940014516 fabrazyme Drugs 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 102000043404 human GLA Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011419 induction treatment Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229960002486 laronidase Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940091827 lumizyme Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000000329 lymphopenic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010048628 rheumatoid vasculitis Diseases 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486697P | 2011-05-16 | 2011-05-16 | |
| US61/486,697 | 2011-05-16 | ||
| PCT/US2012/036405 WO2012158362A1 (en) | 2011-05-16 | 2012-05-03 | Induction of immune tolerance by using methotrexate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013155618A RU2013155618A (ru) | 2015-06-27 |
| RU2674036C2 true RU2674036C2 (ru) | 2018-12-04 |
Family
ID=47177257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013155618A RU2674036C2 (ru) | 2011-05-16 | 2012-05-03 | Индукция иммунологической толерантности, используя метотрексат |
Country Status (28)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809282B2 (en) * | 2010-05-06 | 2014-08-19 | Duke University | Method of reducing titers of antibodies specific for a therapeutic agent |
| CN104623666A (zh) | 2011-04-29 | 2015-05-20 | 西莱克塔生物科技公司 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
| EP3824890A1 (en) | 2011-05-16 | 2021-05-26 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
| MX380164B (es) | 2013-05-03 | 2025-03-12 | Selecta Biosciences Inc | Uso de una macromolécula terapéutica y una composición que comprende nanoportadores sintéticos que se unen a inmunosupresores para reducir la hipersensibilidad tipo i y tipo iv en un sujeto. |
| ES2834129T3 (es) * | 2013-06-04 | 2021-06-16 | Selecta Biosciences Inc | Administración repetida de agentes inmunoterapéuticos específicos de antígeno no inmunosupresores |
| IL292574A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| MX2017013267A (es) | 2015-04-15 | 2018-08-15 | Regeneron Pharma | Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8). |
| JP2016213236A (ja) * | 2015-04-30 | 2016-12-15 | 日東電工株式会社 | 半導体装置用フィルム、及び、半導体装置の製造方法 |
| WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2018209300A1 (en) * | 2017-05-12 | 2018-11-15 | Duke University | Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy |
| TWI821227B (zh) * | 2017-12-22 | 2023-11-11 | 美商健臻公司 | 胺甲喋呤誘發的免疫耐受性之生物標記 |
| JP2023512783A (ja) | 2020-02-08 | 2023-03-29 | ジェンザイム・コーポレーション | ポンペ病を処置するための組成物および方法 |
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090155207A1 (en) * | 2007-11-29 | 2009-06-18 | Hariri Robert J | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080325A (en) | 1976-11-17 | 1978-03-21 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of methotrexate |
| US4558690A (en) | 1982-01-26 | 1985-12-17 | University Of Scranton | Method of administration of chemotherapy to tumors |
| US5108987A (en) | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| DE4000154A1 (de) | 1990-01-04 | 1991-07-11 | Symbiotec Gmbh | Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| US8088916B2 (en) | 2004-03-05 | 2012-01-03 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
| US7884196B2 (en) | 2004-10-06 | 2011-02-08 | Oliver Lawless | Vaccine composition comprising methylated DNA and immunomodulatory motifs |
| MX2008011054A (es) * | 2006-03-02 | 2009-03-03 | Alexion Pharma Inc | Prolongacion de supervivencia de un aloinjerto, mediante la inhibicion de actividad de complemento. |
| WO2008094937A2 (en) | 2007-01-29 | 2008-08-07 | Joslin Diabetes Center, Inc. | Methods of modulating angiogenesis |
| US7914785B2 (en) * | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2077281A1 (en) * | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| HRP20171023T1 (hr) | 2008-10-08 | 2017-10-06 | Cambridge Enterprise Limited | Postupci i pripravci za dijagnozu i liječenje autoimune bolesti sekundarne u odnosu na multiplu sklerozu |
| CA2742910A1 (en) | 2008-11-07 | 2010-05-14 | 4Sc Ag | Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease |
| EP3824890A1 (en) | 2011-05-16 | 2021-05-26 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
-
2012
- 2012-05-03 EP EP20197579.4A patent/EP3824890A1/en active Pending
- 2012-05-03 KR KR1020207027913A patent/KR102316283B1/ko active Active
- 2012-05-03 CN CN202011422509.7A patent/CN113209288A/zh active Pending
- 2012-05-03 MY MYPI2013003998A patent/MY173304A/en unknown
- 2012-05-03 UA UAA201314626A patent/UA117556C2/uk unknown
- 2012-05-03 KR KR1020137032882A patent/KR20140040744A/ko not_active Ceased
- 2012-05-03 WO PCT/US2012/036405 patent/WO2012158362A1/en not_active Ceased
- 2012-05-03 PH PH1/2013/502256A patent/PH12013502256A1/en unknown
- 2012-05-03 SG SG2013082003A patent/SG194802A1/en unknown
- 2012-05-03 CN CN201811398468.5A patent/CN109620830A/zh active Pending
- 2012-05-03 EP EP12785624.3A patent/EP2709627B1/en active Active
- 2012-05-03 US US14/116,486 patent/US20140135337A1/en not_active Abandoned
- 2012-05-03 JP JP2014511390A patent/JP6174572B2/ja active Active
- 2012-05-03 ES ES12785624T patent/ES2836823T3/es active Active
- 2012-05-03 KR KR1020197033979A patent/KR102163285B1/ko active Active
- 2012-05-03 CA CA2835819A patent/CA2835819A1/en not_active Abandoned
- 2012-05-03 PE PE2013002499A patent/PE20140469A1/es not_active Application Discontinuation
- 2012-05-03 CN CN201910138372.3A patent/CN110124039A/zh active Pending
- 2012-05-03 CN CN201280035299.3A patent/CN103648501A/zh active Pending
- 2012-05-03 RU RU2013155618A patent/RU2674036C2/ru active
- 2012-05-03 AU AU2012256281A patent/AU2012256281B2/en active Active
- 2012-05-03 MX MX2013013445A patent/MX2013013445A/es unknown
- 2012-05-03 BR BR112013029501A patent/BR112013029501A2/pt not_active Application Discontinuation
- 2012-05-03 PT PT127856243T patent/PT2709627T/pt unknown
-
2013
- 2013-11-04 IL IL229245A patent/IL229245B/en active IP Right Grant
- 2013-11-06 ZA ZA2013/08315A patent/ZA201308315B/en unknown
- 2013-11-13 TN TNP2013000472A patent/TN2013000472A1/fr unknown
- 2013-11-14 GT GT201300278A patent/GT201300278A/es unknown
- 2013-11-14 NI NI201300121A patent/NI201300121A/es unknown
- 2013-11-15 DO DO2013000268A patent/DOP2013000268A/es unknown
- 2013-11-15 CL CL2013003298A patent/CL2013003298A1/es unknown
- 2013-12-04 MA MA36522A patent/MA35165B1/fr unknown
- 2013-12-05 CO CO13286019A patent/CO6841993A2/es not_active Application Discontinuation
- 2013-12-13 EC ECSP13013081 patent/ECSP13013081A/es unknown
-
2017
- 2017-03-03 JP JP2017040046A patent/JP6381707B2/ja active Active
-
2018
- 2018-08-02 JP JP2018145564A patent/JP6694020B2/ja active Active
-
2020
- 2020-03-24 US US16/828,407 patent/US11672802B2/en active Active
- 2020-08-23 IL IL276879A patent/IL276879B/en unknown
-
2023
- 2023-04-28 US US18/141,128 patent/US20230372347A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090155207A1 (en) * | 2007-11-29 | 2009-06-18 | Hariri Robert J | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders |
Non-Patent Citations (1)
| Title |
|---|
| JOSEPH A. et al. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model // Clin Exp Immunol. 2008 Apr; 152(1): 138-46. GARMAN R.D. et al. Methotrexate reduces antibody responses to recombinant human α-galactosidase A therapy in a mouse model of Fabry disease // Clin Exp Immunol. 2004 Sep; 137(3): 496-502. SAKUMA Y. et al. Short-course methotrexate and long-term acceptance of fully allogeneic rat cardiac grafts: a possible mechanismof tolerance // Transpl Immunol. 2002 Jun; 10(1): 49-54. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2674036C2 (ru) | Индукция иммунологической толерантности, используя метотрексат | |
| Joseph et al. | Transient low-dose methotrexate induces tolerance to murine anti-thymocyte globulin and together they promote long-term allograft survival | |
| US20210236512A1 (en) | Clozapine for the treatment of a immunoglobulin driven b cell disease | |
| HK40053503A (en) | Induction of immune tolerance using methotrexate | |
| HK40053628A (en) | Induction of immune tolerance by using methotrexate | |
| HK40007634A (en) | Induction of immune tolerance by using methotrexate | |
| HK40012743A (en) | Induction of immune tolerance by using methotrexate | |
| OA16781A (en) | Induction of immune tolerance by using methotrexate. | |
| NZ716716B2 (en) | Induction of immune tolerance by using methotrexate | |
| HK1194668B (en) | Induction of immune tolerance by using methotrexate | |
| HK1194668A (en) | Induction of immune tolerance by using methotrexate | |
| NZ617575B2 (en) | Induction of immune tolerance by using methotrexate | |
| NZ742216B2 (en) | Induction of immune tolerance by using methotrexate | |
| Brooks | The effects of hemizygous CD45 expressions on the Fasl (gld)/(gld) autoimmune syndrome | |
| Elliott | Neutrophils as the key mediators of antibody-mediated arthritis and edema: The central role of Syk | |
| Trambley | Costimulation blockade in transplantation: Limitations and adjunct therapies |